Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Cornelis N. De Jong; Ellen Meijer; Katerina Bakunina; Erfan Nur; Marinus van Marwijk Kooij; Marco R. de Groot; Michel van Gelder; Johan A. Maertens; Jurgen H.E. Kuball; Dries Deeren; Bronno van der Holt; Jan J. Cornelissen; Annoek E.C. Broers

doi:10.1182/blood-2019-124659

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Cornelis N. De Jong, Ellen Meijer, Katerina Bakunina, Erfan Nur, Marinus van Marwijk Kooij, Marco R. de Groot, Michel van Gelder, Johan A. Maertens, Jurgen H.E. Kuball, Dries Deeren, Bronno van der Holt, Jan J. Cornelissen, Annoek E.C. Broers

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Original language	English
Pages (from-to)	1
Number of pages	1
Journal	Blood
Volume	134
Issue number	Supplement_1
DOIs	https://doi.org/10.1182/blood-2019-124659
Publication status	Published - 13 Nov 2019

Access to Document

10.1182/blood-2019-124659

Cite this

De Jong, C. N., Meijer, E., Bakunina, K., Nur, E., van Marwijk Kooij, M., de Groot, M. R., van Gelder, M., Maertens, J. A., Kuball, J. H. E., Deeren, D., van der Holt, B., Cornelissen, J. J., & Broers, A. E. C. (2019). Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. Blood, 134(Supplement_1), 1. https://doi.org/10.1182/blood-2019-124659

@article{7ed8c54e15054ab084b71b665695b3ef,

title = "Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors",

abstract = "DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.",

author = "{De Jong}, {Cornelis N.} and Ellen Meijer and Katerina Bakunina and Erfan Nur and {van Marwijk Kooij}, Marinus and {de Groot}, {Marco R.} and {van Gelder}, Michel and Maertens, {Johan A.} and Kuball, {Jurgen H.E.} and Dries Deeren and {van der Holt}, Bronno and Cornelissen, {Jan J.} and Broers, {Annoek E.C.}",

note = "{\textcopyright} 2019 by The American Society of Hematology.",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/blood-2019-124659",

language = "English",

volume = "134",

pages = "1",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Supplement_1",

}

De Jong, CN, Meijer, E, Bakunina, K, Nur, E, van Marwijk Kooij, M, de Groot, MR, van Gelder, M, Maertens, JA, Kuball, JHE, Deeren, D, van der Holt, B, Cornelissen, JJ & Broers, AEC 2019, 'Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors', Blood, vol. 134, no. Supplement_1, pp. 1. https://doi.org/10.1182/blood-2019-124659

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. / De Jong, Cornelis N.; Meijer, Ellen; Bakunina, Katerina et al.
In: Blood, Vol. 134, No. Supplement_1, 13.11.2019, p. 1.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation

T2 - Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

AU - De Jong, Cornelis N.

AU - Meijer, Ellen

AU - Bakunina, Katerina

AU - Nur, Erfan

AU - van Marwijk Kooij, Marinus

AU - de Groot, Marco R.

AU - van Gelder, Michel

AU - Maertens, Johan A.

AU - Kuball, Jurgen H.E.

AU - Deeren, Dries

AU - van der Holt, Bronno

AU - Cornelissen, Jan J.

AU - Broers, Annoek E.C.

PY - 2019/11/13

Y1 - 2019/11/13

N2 - DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

AB - DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

UR - http://www.scopus.com/inward/record.url?scp=85074960800&partnerID=8YFLogxK

U2 - 10.1182/blood-2019-124659

DO - 10.1182/blood-2019-124659

M3 - Article

C2 - 31723985

AN - SCOPUS:85074960800

SN - 0006-4971

VL - 134

SP - 1

JO - Blood

JF - Blood

IS - Supplement_1

ER -

Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this